Analysts project 291.37% upside potential for MindMed (MNMD) in treating anxiety and depression

From Yahoo Finance: 2025-05-21 11:18:00

Mind Medicine (MindMed) Inc. (MNMD) is a clinical-stage biopharmaceutical company focusing on innovative treatments for mental health disorders like anxiety and depression. They are in Phase 3 trials for MM120, showing promise in treating anxiety and depression with lasting effects. With a strong cash position, analysts project a 291.37% upside potential.

MindMed ranks 8th on the list of 13 Best Multibagger Stocks to Invest in Now. While MNMD shows promise, some AI stocks are seen as having greater potential for higher returns. For those seeking a stock with 100x upside potential, an AI stock option is recommended.

MindMed’s financial stability, with a cash balance of $245.5 million, supports their progress through 2027. Wall Street analysts anticipate a twelve-month average share price of $24.50, offering a 291.37% upside potential. They are eagerly awaiting top-line results from the Phase 3 trials for MM120, expected to be a significant milestone in mental health treatment.



Read more at Yahoo Finance: Analysts See 285% Upside Potential